The abstract is read at the publisher; the summary is JClub's.
In Chinese adults with chronic hepatitis B, pradefovir mesylate achieved non-inferior HBV DNA suppression at week 48 versus tenofovir disoproxil fumarate, with HBeAg-positive and HBeAg-negative results within the -12% margin.
- Why it matters: Tenofovir disoproxil fumarate is effective but can raise renal and bone safety concerns, creating a need for comparable antiviral efficacy with improved tolerability.
- What they did: In an ongoing randomized, double-blind phase 3 trial at 58 sites in China, 908 treated patients received 45 mg daily pradefovir or 300 mg daily TDF (2:1), with HBV DNA <29 IU/mL at week 48 as the primary endpoint.
- The result: At week 96, HBeAg-positive patients had a greater HBsAg decline (≥1 log10 IU/mL: 39.3% vs 29.9%), and pradefovir showed fewer drug-related adverse events (58.6% vs 71.9%) with improved bone/renal safety.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.